Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?

Natera is Druckenmiller’s No. 1 holding, with its Q2 revenue up 37.7% YoY to $752.8M and tests processed rising 22.4% YoY to 1.04M+. Oncology drove growth, including a 56% YoY increase to ~238,000 MRD oncology tests, supported by Signatera’s expanding regulatory approvals (US bladder companion diagnostic; Japan colorectal approval; EU IVDR certification). Despite strong growth, the article flags valuation risk—Natera trades at ~17x trailing 12-month sales while remaining unprofitable—so near-term buy enthusiasm is tempered.

Analysis

NTRA is now priced as a compounding platform, not a clinical-test vendor; that matters because platform multiples are fragile when the market sees any slowdown in adoption, reimbursement, or international conversion. At ~17x sales, the equity is implicitly discounting several years of sustained double-digit growth plus margin leverage, so the near-term upside from good execution is smaller than the downside from even a modest miss.

The second-order issue is that oncology MRD looks like a winner-take-most workflow fight: once a hospital system standardizes on a test, switching costs rise, but payer scrutiny also rises as utilization expands. That creates a mismatch between regulatory wins and revenue durability—approvals can accelerate ordering, yet reimbursement and guideline adoption are what convert that into durable cash flow. Competitively, this is most relevant for liquid biopsy peers like GH and for incumbent lab networks such as LH/DGX, which could lose share if MRD becomes embedded in surveillance pathways.

Time horizon matters. Over the next 1-3 months, the stock likely trades on volume growth, gross margin, and any commentary on payer coverage rather than on the headline approval cadence. Over 6-18 months, the key falsifier is whether growth decelerates below the market’s implied runway; if oncology test growth or sequential test acceleration rolls over, the multiple could compress sharply because there is no earnings support underneath the valuation.

Key Decisions for Investors

• Do not chase NTRA here; wait for the next quarterly print or reimbursement update before adding exposure. Entry should require either sustained oncology test acceleration or gross margin expansion, otherwise the risk/reward is poor at ~17x sales.
• If already long NTRA, hedge valuation risk with a 1-2 month collar or covered calls into strength; the thesis is execution-driven, so monetizing elevated implied volatility is preferable to paying full price for momentum.
• Conditional relative-value trade: long GH / short NTRA only if NTRA trades another 10-15% higher without a corresponding revision to revenue or coverage assumptions. Use this as a mean-reversion expression on diagnostics valuation, not a fundamental short of the category.
• Set an alert on the next earnings release for MRD volume growth, sequential oncology test mix, and gross margin. A deceleration in any two of those three is the clearest signal that the multiple should de-rate.